Search

Your search keyword '"Matthias Rothermundt"' showing total 105 results

Search Constraints

Start Over You searched for: Author "Matthias Rothermundt" Remove constraint Author: "Matthias Rothermundt"
105 results on '"Matthias Rothermundt"'

Search Results

1. Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia

2. Distinct molecular phenotypes in male and female schizophrenia patients.

3. Molecular sex differences in human serum.

4. Molecular serum signature of treatment resistant depression

5. Normal Cerebellar Development in S100B-Deficient Mice

6. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients

7. S100B overexpression increases behavioral and neural plasticity in response to the social environment during adolescence

8. Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls

9. Clinical use of phosphorylated proteins in blood serum analysed by immobilised metal ion affinity chromatography and mass spectrometry

10. Blood-based immune-endocrine biomarkers of treatment response in depression

11. Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation

12. Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy

13. The kynurenine pathway in major depression: Haplotype analysis of three related functional candidate genes

14. Identification of a biological signature for schizophrenia in serum

15. Neural correlates of set-shifting: decomposing executive functions in schizophrenia

16. Neuropeptide S receptor gene — converging evidence for a role in panic disorder

17. S100B Serum Levels and Word Memory Processing in Remitted Major Depression as Reflected by Brain Potentials

18. Association Between Cytokines and Cerebral MRI Changes in the Aging Brain

19. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia

20. Association analysis of Rgs7 variants with panic disorder

21. Distinct regulation of brain-derived neurotrophic factor and noradrenaline in S100B knockout mice

22. Reduced implicit and explicit sequence learning in first-episode schizophrenia

23. Therapeutic strategies for catatonia in paraneoplastic encephalitis

24. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: A proton magnetic resonance spectroscopy study

25. Autocrine S100B effects on astrocytes are mediated via RAGE

26. Prenatal immune activation in mice blocks the effects of environmental enrichment on exploratory behavior and microglia density

27. Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset

28. Serum proteomic profiling of major depressive disorder

29. Psychische Erkrankungen und Immunsystem

30. The Impact of the Selective Monoamine Reuptake Inhibitors Reboxetine and Citalopram on Visually-Evoked Event-Related Potentials in Depressed Patients

31. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment

32. Immunological research in clinical psychiatry: report on the consensus debate during the 7th expert meeting on psychiatry and immunology

33. Traumatische Trauer - ein eigenständiges Krankheitsbild?

34. Different immune patterns in melancholic and non-melancholic major depression

35. Cytokine production in unmedicated and treated schizophrenic patients

36. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment

37. Effects of amantadine treatment on in vitro production of interleukin-2 in de-novo patients with idiopathic Parkinson's disease

38. Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways

39. Clinical psychoneuroimmunology

40. Antipsychotic treatment of acute paranoid schizophrenia patients with olanzapine results in altered glycosylation of serum glycoproteins

41. Naturalistic pharmacotherapy of acute episodes of schizophrenic disorders in comparison to treatment guidelines

42. Impaired water-maze performance and altered adult hippocampal neurogenesis in histamine H1-receptor knockout mice

43. Functional assessment of a promoter polymorphism in S100B, a putative risk variant for bipolar disorder

44. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia

45. S100B in schizophrenia: an update

46. Psychotherapie unter den Bedingungen einer zwangsweisen Unterbringung

47. Systemic inflammation (Interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study

48. Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality

49. Adenosine A2A receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder

50. Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals

Catalog

Books, media, physical & digital resources